Athira Pharma ATHA
$ 0.69
7.43%
Quarterly report 2024-Q3
added 11-07-2024
Athira Pharma Balance Sheet 2011-2024 | ATHA
Annual Balance Sheet Athira Pharma
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-89 M | -94.1 M | -109 M | -60.6 M | -503 K | -2.6 M | - | - | - | - | - | - | - |
Long Term Debt |
1.22 M | 1.58 M | 1.63 M | - | 1.55 M | 722 K | - | - | - | - | - | - | - |
Long Term Debt Current |
368 K | 326 K | 288 K | 124 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 876 K | 20.6 M | 19.2 M | - | - | - | - | - | - | - |
Total Current Liabilities |
28.8 M | 21.4 M | 9.29 M | 4.4 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
30.1 M | 23 M | 10.9 M | 5.28 M | 21.9 M | 19.8 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-309 M | -192 M | -95.9 M | - | -21.1 M | -15.9 M | - | - | - | - | - | - | - |
Total Assets |
160 M | 258 M | 332 M | 280 M | 2.19 M | 4.93 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
90.6 M | 96 M | 111 M | 60.6 M | - | - | - | - | - | - | - | - | - |
Book Value |
130 M | 235 M | 321 M | 274 M | -19.7 M | -14.9 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
130 M | 235 M | 321 M | 274 M | -19.7 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Athira Pharma
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
912 K | 1.02 M | 1.12 M | 1.22 M | 1.31 M | 1.41 M | 1.5 M | 1.58 M | 1.67 M | 1.75 M | 1.55 M | 1.63 M | 1.71 M | 1.78 M | 1.7 M | 876 K | 876 K | 876 K | 876 K | 1.55 M | 1.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
28.7 M | 27.9 M | 26.7 M | 30.1 M | 29.9 M | 23.1 M | 21.6 M | 23 M | 11.9 M | 11.4 M | 11 M | 10.9 M | 11.1 M | 9.42 M | 6.2 M | 5.28 M | 5.28 M | 5.28 M | 5.28 M | 4.86 M | 4.86 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-391 M | -362 M | -336 M | -309 M | -282 M | -249 M | -219 M | -192 M | -161 M | -141 M | -117 M | -95.9 M | -79.6 M | -63.9 M | -49.9 M | -41 M | -41 M | -41 M | -41 M | -21.1 M | -21.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
86.2 M | 111 M | 133 M | 160 M | 185 M | 208 M | 233 M | 258 M | 274 M | 292 M | 313 M | 332 M | 347 M | 360 M | 369 M | 280 M | 280 M | 280 M | 280 M | 2.19 M | 2.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
68.9 M | 73.8 M | 77.8 M | 90.6 M | 110 M | 114 M | 105 M | 96 M | 87 M | 95.1 M | 118 M | 111 M | 107 M | 132 M | 128 M | 60.6 M | 60.6 M | 60.6 M | 60.6 M | 2.06 M | 2.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
57.6 M | 83.3 M | 107 M | 130 M | 155 M | 185 M | 211 M | 235 M | 262 M | 281 M | 302 M | 321 M | 336 M | 351 M | 363 M | 274 M | 274 M | 274 M | 274 M | -2.67 M | -2.67 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
57.6 M | 83.3 M | 107 M | 130 M | 155 M | 185 M | 211 M | 235 M | 262 M | 281 M | 302 M | 321 M | 336 M | 351 M | 363 M | 274 M | 274 M | 274 M | 274 M | -19.7 M | -19.7 M | -17.4 M | - | -14.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency